Insider Trading July 9, 2026 05:54 PM

HRT Financial Disposes of Shuttle Pharmaceuticals Holdings Amid Merger Activity and Stock Split

Insider transaction coincides with corporate restructuring, reverse split, and crypto mining expansion as SHPH shares face prolonged decline

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
SHPH

HRT Financial LP, which holds a 10% stake in Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH), executed a $100,460 sale of common stock across two days in early July. The disposal occurs as the company finalizes a merger with United Dogecoin Inc., secures renewable energy infrastructure for cryptocurrency mining, and prepares for a 10-for-1 reverse stock split. SHPH shares have declined 92% over the past year, trading at $3.28, while the firm continues to hold 52,274 shares post-transaction.

HRT Financial Disposes of Shuttle Pharmaceuticals Holdings Amid Merger Activity and Stock Split
SHPH
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • HRT Financial LP sold $100,460 in SHPH common stock across two days in early July, reducing its direct holdings to 52,274 shares.
  • Shuttle Pharmaceuticals completed a merger with United Dogecoin Inc., issued 8,000 shares of Series B-1 Convertible Preferred Stock, and approved a 10-for-1 reverse stock split.
  • SHPH shares have declined 92% over the past year and 83% over the last six months, trading at $3.28, while United Dogecoin advances renewable energy mining infrastructure.

HRT Financial LP, a significant 10% shareholder in Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH), has completed a series of equity dispositions totaling $100,460 in common stock. The transactions were executed across two distinct days in early July, with the firm offloading shares at prices ranging between $3.33 and $3.52 per share. On July 7, 2026, HRT Financial sold 10,580 shares at a price of $3.33. The following day, July 8, 2026, the entity disposed of an additional 18,531 shares at $3.52 per share. These sales were conducted directly by HRT Financial LP, and the resulting position leaves the firm with a direct holding of 52,274 shares of Shuttle Pharmaceuticals common stock. The transaction report was filed on July 9, 2026, covering the period ending June 29, 2026.

The insider activity unfolds against a backdrop of significant corporate restructuring and market volatility. Shuttle Pharmaceuticals has announced the completion of its merger with United Dogecoin Inc., a transaction that establishes United Dogecoin as a wholly owned subsidiary. As part of this consolidation, Shuttle issued 8,000 shares of Series B-1 Convertible Preferred Stock to United Dogecoin equity holders. These preferred shares carry conversion rights into approximately 32,264,000 shares of common stock, contingent upon receiving stockholder approval. Concurrently, Shuttle Pharmaceuticals has approved a 10-for-1 reverse stock split of its common stock, which is set to take effect shortly. Following the split, the company’s common stock will continue trading on the Nasdaq Capital Market under the ticker symbol SHPH on a split-adjusted basis.

Market performance for SHPH has demonstrated substantial downward pressure. Shares currently trade at $3.28, reflecting a 92% decline over the past year. Analysis indicates the stock has fared poorly over the last month, contributing to a broader trend where shares have fallen 83% over a six-month period. Despite this trajectory, some analysis suggests the stock may appear undervalued at current levels, though this stands in contrast to the recent price action.

In related operational developments, United Dogecoin has advanced its cryptocurrency mining infrastructure. The company has purchased ElphaPex DG1+ mining units and secured a mining site with access to renewable energy. United Dogecoin anticipates its first fleet of mining units becoming operational within approximately 60 days, dependent on delivery and installation schedules. These units are designed specifically for Dogecoin and Litecoin mining operations. Furthermore, Shuttle Pharmaceuticals has confirmed a purchase order option for up to 3,000 ElphaPex Scrypt mining rigs to support these mining activities, signaling a strategic expansion into digital asset infrastructure.

The intersection of insider selling, corporate restructuring, and operational pivots presents a complex picture for stakeholders. The merger and reverse split are designed to consolidate capital structure, yet the prolonged stock decline raises questions about market confidence. The shift toward cryptocurrency mining introduces operational risks related to technology deployment and energy logistics, while the convertible nature of the preferred stock issued to United Dogecoin holders introduces potential dilution dynamics for existing common shareholders. The market impact spans the healthcare and biotech sectors, where SHPH operates, as well as the cryptocurrency and digital asset mining sector, reflecting the company's strategic diversification.

Risks

  • Potential dilution from the conversion of 8,000 shares of Series B-1 Convertible Preferred Stock into approximately 32,264,000 common shares, pending stockholder approval.
  • Operational and delivery risks associated with the deployment of ElphaPex mining units and the expansion into cryptocurrency mining, dependent on a 60-day timeline.
  • Prolonged stock price decline of 92% over the past year may indicate broader market skepticism or liquidity concerns impacting the healthcare and cryptocurrency sectors.

More from Insider Trading

WRAP Technologies CEO Scot Cohen Acquires Shares Amid Product Launches and Regulatory Clarity Jul 9, 2026 EverCommerce CEO Eric Remer Divests $199,734 in EVCM Stock Under Pre-Arranged Plan Jul 9, 2026 Samsara CEO Sanjit Biswas Executes $9.67 Million Share Sale Under Pre-Arranged Plan Jul 9, 2026 Samsara's CTO Executes Multi-Million Dollar Share Divestment Under Pre-Planned Trading Schedule Jul 9, 2026 Concentrix CEO Purchases Shares Amid Earnings Miss and Downgraded Outlook Jul 9, 2026